Cellectis S.A. (CLLS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 20, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLLS SEC filings page.
Cellectis S.A. (CLLS) reported $72.9M in revenue for fiscal year 2025, up 75.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cellectis remains a development-stage business where revenue is scaling, but research spending and financing costs still keep cash generation negative.
From FY2024 to FY2025, revenue increased75.8% while research and development rose only3.3% , yet operating cash flow swung from positive$23.0M to-$39.4M . Interest expense rose136.3% to$51.1M , showing that reported growth has not translated into self-funded operations because financing costs are absorbing part of the improvement.
Research and development reached
The liabilities-to-equity ratio climbed from 1.9x in FY2024 to 3.3x in FY2025, indicating equity declined faster than liabilities. The current ratio was
Financial Health Signals
Cellectis S.A. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cellectis S.A. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Cellectis S.A. reported a net loss of $67.6M while operations used $39.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cellectis S.A. reported an operating loss of $33.1M against $51.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cellectis S.A. generated $72.9M in revenue in fiscal year 2025. This represents an increase of 75.8% from the prior year.
Cellectis S.A.'s EBITDA was -$13.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Cellectis S.A. reported a net loss of $67.6M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cellectis S.A. earned -$0.67 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
Cellectis S.A. recorded an outflow of $41.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 304.7% from the prior year.
Cellectis S.A. held $61.5M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Cellectis S.A.'s gross margin was 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. That is unchanged from the prior year.
Cellectis S.A.'s operating margin was -45.3% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Cellectis S.A.'s net profit margin was -92.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.1 percentage points from the prior year.
Cellectis S.A.'s ROE was -89.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 61.0 percentage points from the prior year.
Capital Allocation
Cellectis S.A. invested $93.5M in research and development in fiscal year 2025. This represents an increase of 3.3% from the prior year.
Cellectis S.A. invested $2.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 8.6% from the prior year.
Not reported for fiscal year 2025.
CLLS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.9M+75.8% | $41.5M+5397.4% | $755K-96.1% | $19.2M-36.8% | $30.3M-40.6% | $51.1M+236.1% | $15.2M+19.3% | $12.7M-49.5% | $25.2M-43.8% | $44.8M-19.8% | $55.9M+58.9% | $35.2M |
| Cost of Revenue | $0n/m | $0-100.0% | $737K-58.4% | $1.8M-3.9% | $1.8M-5.5% | $2.0M-82.9% | $11.4M+315.9% | $2.7M+4.5% | $2.6M | N/A | N/A | N/A |
| Gross Profit | $72.9M+75.8% | $41.5M+230483.3% | $18K-99.9% | $17.4M-39.0% | $28.5M-42.0% | $49.1M+1192.9% | $3.8M-62.0% | $10.0M-55.7% | $22.6M | N/A | N/A | N/A |
| R&D Expenses | $93.5M+3.3% | $90.5M+3.3% | $87.6M-10.1% | $97.5M-17.3% | $117.8M+52.9% | $77.0M-16.3% | $92.0M+20.2% | $76.6M-3.4% | $79.2M+1.0% | $78.5M+34.9% | $58.2M | N/A |
| Operating Income | -$33.1Mn/m | -$59.6Mn/m | -$97.3Mn/m | -$89.7Mn/m | -$103.5Mn/m | -$42.3Mn/m | -$123.6Mn/m | -$105.1Mn/m | -$92.7Mn/m | -$67.3Mn/m | -$31.0Mn/m | -$7.0M |
| EBITDA | -$13.0Mn/m | -$39.7Mn/m | -$78.8Mn/m | -$71.2Mn/m | -$89.3Mn/m | -$34.5Mn/m | -$116.7Mn/m | -$102.7Mn/m | -$89.3Mn/m | -$65.1Mn/m | -$29.0M | N/A |
| Interest Expense | $51.1M+136.3% | $21.6M-46.8% | $40.6M+10854.7% | $371K+0.8% | $368K+404.1% | $73K+2333.3% | $3K-92.3% | $39Kn/m | $0-100.0% | $7.1M+710000.0% | $1K | N/A |
| Income Tax | -$423Kn/m | $0-100.0% | $371K+326.4% | $87Kn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Net Income | -$67.6Mn/m | -$36.8Mn/m | -$101.1Mn/m | -$106.1Mn/m | -$114.2Mn/m | -$81.1Mn/m | -$102.1Mn/m | -$78.7Mn/m | -$99.4Mn/m | -$67.3Mn/m | -$22.8Mn/m | -$1.3M |
| EPS (Basic) | -$0.67n/m | -$0.41 | -$1.77n/m | -$2.33n/m | -$2.55n/m | -$1.91n/m | -$2.41n/m | -$1.93n/m | -$2.78n/m | -$1.91n/m | -$0.67 | N/A |
| EPS (Diluted) | -$0.67n/m | -$0.41 | -$1.77n/m | -$2.33n/m | -$2.55n/m | -$1.91n/m | -$2.41n/m | -$1.93n/m | -$2.78n/m | -$1.91n/m | -$0.67 | N/A |
| Diluted Shares (Avg) | 100M+10.7% | 91M | 57M+25.2% | 46M+1.6% | 45M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: SG&A Expenses.
CLLS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $324.7M-15.3% | $383.5M+14.7% | $334.3M+28.0% | $261.2M-31.6% | $382.1M-18.6% | $469.5M+0.4% | $467.5M-6.7% | $500.8M+50.5% | $332.9M+0.4% | $331.4M-10.7% | $371.3M+122.2% | $167.1M |
| Current Assets | $236.2M-17.7% | $287.1M+23.2% | $233.0M+90.9% | $122.0M-45.9% | $225.4M-28.5% | $315.4M-19.5% | $391.5M-19.7% | $487.6M+50.9% | $323.2M+3.4% | $312.5M-14.1% | $363.9M+127.0% | $160.3M |
| Cash & Equivalents | $61.5M-57.0% | $143.3M+4.8% | $136.7M+46.7% | $93.2M-49.8% | $185.6M-23.0% | $241.1M-29.2% | $340.5M-24.6% | $451.5M+76.1% | $256.4M+0.7% | $254.6M-25.6% | $342.1M+150.8% | $136.4M |
| Inventory | N/A | N/A | N/A | $0n/m | $0-100.0% | $1.6M-44.8% | $2.9M+953.5% | $275K+10.0% | $250K+111.9% | $118K | N/A | N/A |
| Goodwill | $535K-52.1% | $1.1M+66.3% | $671K-6.5% | $718K-61.3% | $1.9M+17.0% | $1.6M+43.0% | $1.1M-12.6% | $1.3M-11.4% | $1.4M+6.6% | $1.3M+29.0% | $1.0M-16.5% | $1.2M |
| Total Liabilities | $248.8M-1.5% | $252.5M+1.2% | $249.6M+74.2% | $143.2M-10.9% | $160.8M-13.4% | $185.7M+21.9% | $152.3M+66.4% | $91.5M+34.6% | $68.0M+16.0% | $58.6M-31.1% | $85.1M-8.8% | $93.3M |
| Current Liabilities | $145.8M-12.3% | $166.3M+7.2% | $155.1M+222.3% | $48.1M-2.5% | $49.3M-5.1% | $52.0M-16.9% | $62.6M+33.6% | $46.9M+3.1% | $45.5M-19.1% | $56.2M-32.9% | $83.8M-7.8% | $90.9M |
| Non-Current Liabilities | $103.1M+19.5% | $86.2M-8.7% | $94.4M+30.6% | $72.3M-24.9% | $96.3M-11.4% | $108.6M+119.9% | $49.4M+1235.4% | $3.7M+7.4% | $3.4M+483.6% | $590K+7.7% | $548K-86.0% | $3.9M |
| Total Equity | $75.9M-42.1% | $131.0M+54.7% | $84.7M-28.2% | $118.0M-46.7% | $221.3M-22.0% | $283.8M-9.9% | $315.1M-23.0% | $409.3M+54.5% | $264.9M-2.9% | $272.8M-4.7% | $286.2M+287.8% | $73.8M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | -$506.0Mn/m | -$406.4Mn/m | -$326.6Mn/m | -$253.7Mn/m | -$209.7Mn/m | -$185.1M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Long-Term Debt.
CLLS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$39.4M-271.4% | $23.0Mn/m | -$24.7Mn/m | -$87.4Mn/m | -$104.6Mn/m | -$80.3Mn/m | -$69.1Mn/m | -$68.1Mn/m | -$52.3Mn/m | -$32.7M-1010.9% | $3.6M | N/A |
| Depreciation & Amortization | $20.1M+1.1% | $19.8M+7.1% | $18.5M+0.5% | $18.4M+30.2% | $14.2M+80.7% | $7.8M+13.9% | $6.9M+189.2% | $2.4M-29.5% | $3.4M+52.5% | $2.2M+14.1% | $1.9M | N/A |
| Capital Expenditures | $2.4M-8.6% | $2.6M+140.7% | $1.1M-55.9% | $2.4M-86.9% | $18.5M-57.9% | $44.1M+241.3% | $12.9M+173.9% | $4.7M+97.9% | $2.4M-82.6% | $13.7M+217.3% | $4.3M | N/A |
| Free Cash Flow | -$41.8M-304.7% | $20.4Mn/m | -$25.8Mn/m | -$89.9Mn/m | -$123.1Mn/m | -$124.3Mn/m | -$82.1Mn/m | -$72.9Mn/m | -$54.7Mn/m | -$46.4Mn/m | -$725K | N/A |
| Investing Cash Flow | -$29.5Mn/m | -$102.8Mn/m | -$15.5Mn/m | -$2.8M-137.9% | $7.3Mn/m | -$54.3Mn/m | -$35.9M-200.7% | $35.6M+1896.8% | $1.8Mn/m | -$53.1Mn/m | -$7.7M | N/A |
| Financing Cash Flow | -$16.8M-118.8% | $89.1M+7.5% | $82.9M+7137.1% | $1.1M-97.6% | $47.5M+74.0% | $27.3Mn/m | -$3.9M-101.6% | $236.5M+473.1% | $41.3M+8408.5% | $485K-99.8% | $220.6M | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
CLLS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0%0.0pp | 100.0%+97.6pp | 2.4%-88.4pp | 90.8%-3.2pp | 93.9%-2.3pp | 96.2%+71.2pp | 25.0%-53.5pp | 78.5%-11.1pp | 89.6% | N/A | N/A | N/A |
| Operating Margin | -45.3% | -143.5% | -12887.7% | -467.7% | -341.0% | -82.9% | -813.4% | -825.5% | -367.8% | -150.2% | -55.5%-35.6pp | -19.8% |
| Net Margin | -92.7%-4.1pp | -88.6% | -13385.3% | -553.6% | -376.3% | -158.8% | -672.1% | -618.1% | -394.5% | -150.1% | -40.8%-37.1pp | -3.7% |
| Return on Equity | -89.0%-61.0pp | -28.1%+91.3pp | -119.3%-29.3pp | -90.0%-38.4pp | -51.6%-23.0pp | -28.6%+3.8pp | -32.4%-13.2pp | -19.2%+18.3pp | -37.5%-12.9pp | -24.6%-16.7pp | -8.0%-6.2pp | -1.8% |
| Return on Assets | -20.8%-11.2pp | -9.6%+20.7pp | -30.2%+10.4pp | -40.6%-10.7pp | -29.9%-12.6pp | -17.3%+4.6pp | -21.8%-6.1pp | -15.7%+14.1pp | -29.8%-9.6pp | -20.3%-14.1pp | -6.1%-5.4pp | -0.8% |
| Current Ratio | 1.62-0.1x | 1.73+0.2x | 1.50-1.0x | 2.54-2.0x | 4.57-1.5x | 6.06-0.2x | 6.25-4.2x | 10.40+3.3x | 7.11+1.5x | 5.56+1.2x | 4.34+2.6x | 1.76 |
| Liabilities-to-Equity | 3.28+1.4x | 1.93-1.0x | 2.95+1.7x | 1.21+0.5x | 0.73+0.1x | 0.65+0.2x | 0.48+0.3x | 0.220.0x | 0.260.0x | 0.21-0.1x | 0.30-1.0x | 1.26 |
| Asset Turnover | 0.22+0.1x | 0.11+0.1x | 0.00-0.1x | 0.070.0x | 0.080.0x | 0.11+0.1x | 0.030.0x | 0.03-0.1x | 0.08-0.1x | 0.140.0x | 0.15-0.1x | 0.21 |
| FCF Margin | -57.3%-106.4pp | 49.2% | -3419.7% | -468.8% | -405.7% | -243.5% | -540.2% | -572.2% | -217.2% | -103.6% | -1.3% | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cellectis S.A. CLLS | FY2025 | $72.9M | -$67.6M | -92.7% | $97.4M | — |
| enGene Therapeutics Inc. ENGN | FY2025 | N/A | -$117.3M | N/A | $105.9M | — |
| 4D Molecular Therapeutics, Inc. FDMT | FY2025 | $85.2M | -$140.1M | N/A | $609.3M | 72/100 |
| Korro Bio, Inc. KRRO | FY2025 | $6.4M | -$117.3M | N/A | $177.0M | 56/100 |
| Monte Rosa Therapeutics, Inc. GLUE | FY2025 | $123.7M | -$38.6M | -31.2% | $894.1M | 67/100 |
| Abeona Therapeutics Inc. ABEO | FY2025 | $5.8M | $71.2M | N/A | $246.5M | 52/100 |
Where Cellectis S.A. Ranks
Frequently Asked Questions
What is Cellectis S.A.'s annual revenue?
Cellectis S.A. (CLLS) reported $72.9M in total revenue for fiscal year 2025. This represents a 75.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cellectis S.A.'s revenue growing?
Cellectis S.A. (CLLS) revenue grew by 75.8% year-over-year, from $41.5M to $72.9M in fiscal year 2025.
Is Cellectis S.A. profitable?
No, Cellectis S.A. (CLLS) reported a net loss of $67.6M in fiscal year 2025, with a net profit margin of -92.7%.
What is Cellectis S.A.'s EBITDA?
Cellectis S.A. (CLLS) had EBITDA of -$13.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cellectis S.A.'s gross margin?
Cellectis S.A. (CLLS) had a gross margin of 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cellectis S.A.'s operating margin?
Cellectis S.A. (CLLS) had an operating margin of -45.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cellectis S.A.'s net profit margin?
Cellectis S.A. (CLLS) had a net profit margin of -92.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cellectis S.A.'s return on equity (ROE)?
Cellectis S.A. (CLLS) has a return on equity of -89.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cellectis S.A.'s free cash flow?
Cellectis S.A. (CLLS) recorded an outflow of $41.8M in free cash flow during fiscal year 2025. This represents a -304.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cellectis S.A.'s operating cash flow?
Cellectis S.A. (CLLS) recorded an outflow of $39.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cellectis S.A.'s total assets?
Cellectis S.A. (CLLS) had $324.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cellectis S.A.'s capital expenditures?
Cellectis S.A. (CLLS) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cellectis S.A. spend on research and development?
Cellectis S.A. (CLLS) invested $93.5M in research and development during fiscal year 2025.
What is Cellectis S.A.'s current ratio?
Cellectis S.A. (CLLS) had a current ratio of 1.62 as of fiscal year 2025, which is generally considered healthy.
What is Cellectis S.A.'s liabilities-to-equity ratio?
Cellectis S.A. (CLLS) had a liabilities-to-equity ratio of 3.28 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Cellectis S.A.'s return on assets (ROA)?
Cellectis S.A. (CLLS) had a return on assets of -20.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cellectis S.A.'s P/E ratio?
Cellectis S.A. (CLLS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $97.4M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cellectis S.A.'s price-to-sales ratio?
Cellectis S.A. (CLLS) trades at 1.3x sales, its market capitalization divided by $72.9M revenue, FY2025. The market capitalization is $97.4M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cellectis S.A.'s Piotroski F-Score?
Cellectis S.A. (CLLS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cellectis S.A.'s earnings high quality?
Cellectis S.A. (CLLS) reported a net loss of $67.6M while operations used $39.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cellectis S.A. cover its interest payments?
Cellectis S.A. (CLLS) reported an operating loss of $33.1M against $51.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.